Literature DB >> 10919714

Upregulation of vascular endothelial growth factor by cobalt chloride-simulated hypoxia is mediated by persistent induction of cyclooxygenase-2 in a metastatic human prostate cancer cell line.

X H Liu1, A Kirschenbaum, S Yao, M E Stearns, J F Holland, K Claffey, A C Levine.   

Abstract

Upregulation of vascular endothelial growth factor (VEGF) expression induced by hypoxia is crucial event leading to neovascularization. Cyclooxygenase-2, an inducible enzyme that catalyzes the formation of prostaglandins (PGs) from arachidonic acid, has been demonstrated to be induced by hypoxia and play role in angiogenesis and metastasis. To investigate the potential effect of COX-2 on hypoxia-induced VEGF expression in prostate cancer. We examined the relationship between COX-2 expression and VEGF induction in response to cobalt chloride (CoCl2)-simulated hypoxia in three human prostate cancer cell lines with differing biological phenotypes. Northern blotting and ELISA revealed that all three tested cell lines constitutively expressed VEGF mRNA, and secreted VEGF protein to different degrees (LNCaP > PC-3 > PC3ML). However, these cell lines differed in the ability to produce VEGF in the presence of CoCl2-simulated hypoxia. CoCl2 treatment resulted in 40% and 75% increases in VEGF mRNA, and 50% and 95% in protein secretion by LNCaP and PC-3 cell lines, respectively. In contrast, PC-3ML cell line, a PC-3 subline with highly invasive, metastatic phenotype, exhibits a dramatic upregulation of VEGF, 5.6-fold in mRNA and 6.3-fold in protein secretion after treatment with CoCl2. The upregulation of VEGF in PC-3ML cells is accompanied by a persistent induction of COX-2 mRNA (6.5-fold) and protein (5-fold). Whereas COX-2 expression is only transiently induced in PC-3 cells and not affected by CoCl2 in LNCaP cells. Moreover, the increases in VEGF mRNA and protein secretion induced by CoCl2 in PC-3ML cells were significantly suppressed following exposure to NS398, a selective COX-2 inhibitor. Finally, the effect of COX-2 inhibition on CoCl2-induced VEGF production was reversed by the treatment with exogenous PGE2. Our data demonstrate that VEGF induction by cobalt chloride-simulated hypoxia is maintained by a concomitant, persistent induction of COX-2 expression and sustained elevation of PGE2 synthesis in a human metastatic prostate cancer cell line, and suggest that COX-2 activity, reflected by PGE2 production, is involved in hypoxia-induced VEGF expression, and thus, modulates prostatic tumor angiogenesis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10919714     DOI: 10.1023/a:1006728119549

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  38 in total

1.  Activator-protein-1 binding potentiates the hypoxia-induciblefactor-1-mediated hypoxia-induced transcriptional activation of vascular-endothelial growth factor expression in C6 glioma cells.

Authors:  A Damert; E Ikeda; W Risau
Journal:  Biochem J       Date:  1997-10-15       Impact factor: 3.857

Review 2.  Oxygen sensing and molecular adaptation to hypoxia.

Authors:  H F Bunn; R O Poyton
Journal:  Physiol Rev       Date:  1996-07       Impact factor: 37.312

3.  Hypoxia induces cyclooxygenase-2 via the NF-kappaB p65 transcription factor in human vascular endothelial cells.

Authors:  J F Schmedtje; Y S Ji; W L Liu; R N DuBois; M S Runge
Journal:  J Biol Chem       Date:  1997-01-03       Impact factor: 5.157

4.  Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma.

Authors:  N Weidner; P R Carroll; J Flax; W Blumenfeld; J Folkman
Journal:  Am J Pathol       Date:  1993-08       Impact factor: 4.307

5.  NS-398, a novel non-steroidal anti-inflammatory drug with potent analgesic and antipyretic effects, which causes minimal stomach lesions.

Authors:  N Futaki; K Yoshikawa; Y Hamasaka; I Arai; S Higuchi; H Iizuka; S Otomo
Journal:  Gen Pharmacol       Date:  1993-01

6.  Similarities between the oxygen-sensing mechanisms regulating the expression of vascular endothelial growth factor and erythropoietin.

Authors:  M A Goldberg; T J Schneider
Journal:  J Biol Chem       Date:  1994-02-11       Impact factor: 5.157

7.  Induction of vascular endothelial growth factor expression by prostaglandin E2 and E1 in osteoblasts.

Authors:  S Harada; J A Nagy; K A Sullivan; K A Thomas; N Endo; G A Rodan; S B Rodan
Journal:  J Clin Invest       Date:  1994-06       Impact factor: 14.808

8.  Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic.

Authors:  J L Masferrer; B S Zweifel; P T Manning; S D Hauser; K M Leahy; W G Smith; P C Isakson; K Seibert
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-12       Impact factor: 11.205

9.  Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential.

Authors:  M Tsujii; S Kawano; R N DuBois
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-01       Impact factor: 11.205

10.  NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells.

Authors:  X H Liu; S Yao; A Kirschenbaum; A C Levine
Journal:  Cancer Res       Date:  1998-10-01       Impact factor: 12.701

View more
  42 in total

1.  Noninvasive imaging identifies new roles for cyclooxygenase-2 in choline and lipid metabolism of human breast cancer cells.

Authors:  Tariq Shah; Ioannis Stasinopoulos; Flonne Wildes; Samata Kakkad; Dmitri Artemov; Zaver M Bhujwalla
Journal:  NMR Biomed       Date:  2011-09-22       Impact factor: 4.044

2.  A versatile valve-enabled microfluidic cell co-culture platform and demonstration of its applications to neurobiology and cancer biology.

Authors:  Yandong Gao; Devi Majumdar; Bojana Jovanovic; Candice Shaifer; P Charles Lin; Andries Zijlstra; Donna J Webb; Deyu Li
Journal:  Biomed Microdevices       Date:  2011-06       Impact factor: 2.838

3.  Drug-induced regeneration in adult mice.

Authors:  Yong Zhang; Iossif Strehin; Khamilia Bedelbaeva; Dmitri Gourevitch; Lise Clark; John Leferovich; Phillip B Messersmith; Ellen Heber-Katz
Journal:  Sci Transl Med       Date:  2015-06-03       Impact factor: 17.956

4.  Omega 3 but not omega 6 fatty acids inhibit AP-1 activity and cell transformation in JB6 cells.

Authors:  G Liu; D M Bibus; A M Bode; W Y Ma; R T Holman; Z Dong
Journal:  Proc Natl Acad Sci U S A       Date:  2001-06-19       Impact factor: 11.205

5.  Membrane-bound and exosomal metastasis-associated C4.4A promotes migration by associating with the α(6)β(4) integrin and MT1-MMP.

Authors:  Honoré Ngora; Uwe M Galli; Kaoru Miyazaki; Margot Zöller
Journal:  Neoplasia       Date:  2012-02       Impact factor: 5.715

6.  Validation of a device for the active manipulation of the tumor microenvironment during intravital imaging.

Authors:  James K Williams; David Entenberg; Yarong Wang; Alvaro Avivar-Valderas; Michael Padgen; Ashley Clark; Julio A Aguirre-Ghiso; James Castracane; John S Condeelis
Journal:  Intravital       Date:  2016-04-29

7.  Paclitaxel combined with harmine inhibits the migration and invasion of gastric cancer cells through downregulation of cyclooxygenase-2 expression.

Authors:  Kun Sun; Xiao-He Tang; Yi-Kui Xie
Journal:  Oncol Lett       Date:  2015-06-25       Impact factor: 2.967

8.  Identification of proangiogenic genes and pathways by high-throughput functional genomics: TBK1 and the IRF3 pathway.

Authors:  Christian Korherr; Hendrik Gille; Rolf Schäfer; Kerstin Koenig-Hoffmann; Johan Dixelius; Kristi A Egland; Ira Pastan; Ulrich Brinkmann
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-06       Impact factor: 11.205

9.  Synergistic actions of atorvastatin with gamma-tocotrienol and celecoxib against human colon cancer HT29 and HCT116 cells.

Authors:  Zhihong Yang; Hang Xiao; Huanyu Jin; Phillip T Koo; Dorothea J Tsang; Chung S Yang
Journal:  Int J Cancer       Date:  2010-02-15       Impact factor: 7.396

10.  COX-2 expression predicts prostate-cancer outcome: analysis of data from the RTOG 92-02 trial.

Authors:  Li-Yan Khor; Kyounghwa Bae; Alan Pollack; M Elizabeth H Hammond; David J Grignon; Varagur M Venkatesan; Seth A Rosenthal; Mark A Ritter; Howard M Sandler; Gerald E Hanks; William U Shipley; Adam P Dicker
Journal:  Lancet Oncol       Date:  2007-09-18       Impact factor: 41.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.